TRAW Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $0.57
Market Cap (MRQ) $9M
P/E 1.4
EPS $0.82
Revenue $3M
52W Range $0–$3

TRAW Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 4
Ex-date Split Type
Sept. 23, 2024 1-for-25 Reverse
May 21, 2021 1-for-15 Reverse
Sept. 26, 2018 1-for-15 Reverse
June 1, 2016 1-for-10 Reverse

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$3M
2016-12-31 → 2025-12-31
EPS$0.82
2020-12-31 → 2025-12-31
Free Cash Flow·
2019-12-31 → 2019-12-31
Net margin·
2016-12-31 → 2019-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend TRAW 5Y avg Peer Median Verdict
P/E 1.45Y avg ≈-16.8 ≈-16.8 · ·
P/B (MRQ) 5.1 · 2.0 Overvalued
Price / Tangible Book (MRQ) -11.65Y avg ≈25.9 ≈25.9 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 348.6%
Next Report Nov 11, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 14, 2026 $-0.18 $-0.34 47.4%
March 31, 2026 May 15, 2026 $-0.53 $-0.75 29.8%
Dec. 31, 2025 $0.63 $-1.25 150.5%
Dec. 31, 2024 $95.66 $-9.74 1082.0%
Sept. 30, 2024 $95.66 $-9.74 1082.0%
Dec. 31, 2023 $-4.75 $-6.46 26.5%
Sept. 30, 2023 $-5.75 $-7.39 22.2%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 16
Metric Trend 202520242023202220212020201920182017201620152014
Revenue $3M$226.0K$226.0K$226.0K$226.0K$231.0K$2M$1M$787.0K$6M$11M$800.0K
R&D Expense ··$11M$11M$7M$17M$16M$17M$19M$20M$26M$49M
SG&A Expense $9M$12M$9M$8M$9M$8M$8M$8M$7M$9M$10M$15M
Operating Expenses $21M$143M$21M$20M$17M$25M$24M$25M$27M$29M$35M$65M
Operating Income $-18M$-142M$-20M$-20M$-16M$-25M$-22M$-23M$-26M$-24M$-24M$-64M
Interest Expense ···········$2.0K
Interest Income $455.0K$510.0K$1M$651.0K········
Other Non-op $478.0K$289.0K$1M$663.0K$12.0K$48.0K$143.0K$1M$30.0K$62.0K$-35.0K$-52.0K
Pretax Income $9M$-167M$-19M$-19M$-16M$-25M$-21M$-21M$-24M$-20M$-24M$-64M
Income Tax ·····$4.0K$10.0K$-124.0K$13.0K$14.0K$16.0K$19.0K
Net Income $9M$-167M$-19M$-19M$-16M$-25M$-22M$-21M$-24M$-20M$-24M$-64M
EPS (Basic) $0.83$-35.21$-22.57$-0.91$-0.96$-2.17······
EPS (Diluted) $0.82$-35.21$-22.57$-0.91$-0.96$-2.17······
Shares (Basic) 8,228,1691,552,685839,55420,908,23516,832,19811,602,391······
Shares (Diluted) 8,376,3801,552,685839,55420,908,23516,832,19811,602,391······
EBITDA ······$-22M$-23M·$-24M$-24M$-63M
Balance Sheet 22
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents ··$21M$39M·····$21M$20M$44M
Receivables $4M$2M$18.0K$29.0K$28.0K$37.0K$98.0K$35.0K$59.0K$31.0K$2M$132.0K
Prepaid Expense $365.0K$2M$2M$561.0K$332.0K$722.0K$650.0K$760.0K$820.0K$2M$2M$3M
Other Current Assets $89.0K$178.0K$401.0K$40.0K$35.0K$180.0K$140.0K$68.0K$77.0K$73.0K$195.0K$255.0K
Current Assets $8M$25M$23M$39M$55M$20M$23M$18M$5M$23M$23M$47M
PP&E (Net) $7.0K$10.0K$22.0K$24.0K$38.0K$52.0K$50.0K$9.0K$64.0K$152.0K$248.0K$420.0K
PP&E (Gross) ··$84.0K$70.0K$70.0K$70.0K$2M$2M$2M$2M$2M$3M
Accum. Depreciation $77.0K$74.0K$62.0K$46.0K$32.0K$18.0K$2M$2M$2M$2M$2M$2M
Intangibles $3M···········
Other Non-current Assets $104.0K$1.0K$1.0K$1.0K$10.0K$150.0K$150.0K$149.0K$12.0K$12.0K$12.0K$12.0K
Total Assets $11M$25M$23M$39M$55M$20M$24M$18M$5M$23M$23M$47M
Accounts Payable $6M$8M$6M$4M$3M$5M$4M$4M$6M$5M$3M$4M
Accrued Liabilities $5M$3M$3M$4M$3M$5M$4M$4M····
Current Liabilities $11M$12M$9M$8M$6M$10M$8M$8M$10M$10M$8M$10M
Other Non-current Liabilities ···········$1.0K
Total Liabilities $11M$57M$12M$11M$9M$14M$12M$13M$16M$18M$13M$24M
Common Stock $90.0K$36.0K$9.0K$209.0K$209.0K$124.0K$1M$57.0K$8.0K$68.0K$25.0K$217.0K
Retained Earnings $-640M$-649M$-483M$-464M$-445M$-429M$-403M$-382M$-362M$-338M$-319M$-295M
AOCI $6.0K$-42.0K$-23.0K$-33.0K$-14.0K$14.0K$-18.0K$-12.0K$3.0K$-31.0K$-22.0K$-13.0K
Stockholders' Equity $-629.0K$-32M$11M$28M$46M$6M$12M$5M$-12M$4M$10M$23M
Liabilities + Equity $11M$25M$23M$39M$55M$20M$24M$18M$5M$23M$23M$47M
Shares Outstanding 9,067,7743,650,731840,25120,925,99220,895,56312,396,219111,167,3525,674,220718,0786,759,8952,546,41921,703,173
Cash Flow 14
Metric Trend 202520242023202220212020201920182017201620152014
D&A $61.0K$12.0K$16.0K$14.0K$14.0K$13.0K$14.0K$55.0K$88.0K$96.0K$150.0K$434.0K
Stock-based Comp $728.0K$1M$1M$1M$576.0K$369.0K$1M$1M$2M$4M$4M$5M
Deferred Tax ·······$-137.0K·$0$0$0
Amort. of Intangibles $58.0K$0··········
Other Non-cash ······$-390.0K$-3M·$-171.0K$-11M$532.0K
Operating Cash Flow $-18M$-30M$-18M$-16M$-19M$-23M$-21M$-23M$-24M$-16M$-31M$-58M
CapEx $3M$4M$14.0K··$15.0K$55.0K····$228.0K
Investing Cash Flow $-3M$-4M$-14.0K··$-15.0K$-55.0K·····
Stock Issued $6M···$55M$9M$22M$35M··$7M·
Net Stock Activity ······$22M···$7M·
Financing Cash Flow $3M$34M··$56M$19M$27M$36M$6M$17M··
Net Change in Cash $-18M$517.0K$-18M$-16M$36M$-4M$6M$13M$-17M$2M$-24M$-16M
Free Cash Flow ······$-21M····$-58M
Levered FCF ···········$-58M
Profitability 7
Metric Trend 202520242023202220212020201920182017201620152014
Operating Margin ······-994.0%-1895.9%·-427.4%-209.2%-7968.0%
Net Margin ······-985.0%-1675.3%·-354.6%-209.3%-7960.3%
Pretax Margin ······-984.6%-1672.1%·-354.4%-209.6%-7972.0%
EBITDA Margin ······-993.4%-1891.5%·-425.7%-207.9%-7913.8%
ROA ······-103.4%-179.7%·-84.3%-67.8%-83.5%
ROE ······-777.3%652.7%·-274.9%-146.4%-123.5%
ROIC ······-187.6%-429.6%·-552.0%-239.6%-280.3%
Liquidity & Solvency 3
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio ······2.82.1·2.33.04.6
Quick Ratio ······0.00.0·2.12.84.2
Interest Coverage ···········-31872.0
Efficiency 2
Metric Trend 202520242023202220212020201920182017201620152014
Asset Turnover ······0.10.1·0.20.30.0
Receivables Turnover ······32.826.1·7.214.0·
Per Share 3
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share ······$0.10$0.95·$0.64$0.39$1.05
Cash / Share ·········$3.17$0.78$2.01
EPS (TTM) $0.82$-35.21$-22.57$-0.91$-0.96$-2.17······
Growth Rates 3
Metric Trend 202520242023202220212020201920182017201620152014
Revenue YoY 1134.5%0.00%0.00%0.00%-2.2%·······
Revenue CAGR 3Y 131.1%0.00%-0.73%·········
Revenue CAGR 5Y 64.6%···········
Valuation (TTM) 10
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM $3M$226.0K$226.0K$226.0K$226.0K$231.0K$2M$1M$787.0K$6M$11M$800.0K
Net Income TTM $9M$-167M$-19M$-19M$-16M$-25M$-22M$-21M$-24M$-20M$-24M$-64M
Market Cap ······$15.84B$4.49B·$86.32B$1.38T$4.02T
P/E 1.4-0.3-0.8-17.9-66.4-81.2······
P/S ······7256.73656.1·15563.5120030.25020554.3
P/B ······1368.7833.4·20087.4137369.3176562.5
P / Tangible Book ··36.912.028.95307.3······
P / Cash Flow ······-760.5-197.8·-5458.5-44019.0-69671.9
P / FCF ······-758.5····-69397.4
Earnings Yield 72.6%-396.5%-120.4%-5.6%-1.5%-1.2%······

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $3M $226.0K $226.0K $226.0K $226.0K
Net Income $9M $-167M $-19M $-19M $-16M
Diluted EPS $0.82 $-35.21 $-22.57 $-0.91 $-0.96

Institutional owners (13F) 35 filers · $5.2M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 35
Value held $5.2M
New positions 13
Exited positions 6
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
13 (-1 vs prior Q) 6 (-1 vs prior Q) 9 (+7 vs prior Q) 8 (+4 vs prior Q) +2.5M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
ORBIMED ADVISORS LLC $1,014,709 1,203,260 19.55% Shares
Ally Bridge Group (NY) LLC $663,033 786,236 12.77% Shares
ADAGE CAPITAL PARTNERS GP, L.L.C. $615,609 730,000 11.86% Shares
ADAR1 Capital Management, LLC $504,065 597,729 9.71% Shares
Lynx1 Capital Management LP $471,801 559,470 9.09% Shares
Ikarian Capital, LLC $403,217 478,142 7.77% Shares
SPHERA FUNDS MANAGEMENT LTD. $336,043 398,486 6.47% Shares
VANGUARD CAPITAL MANAGEMENT LLC $278,231 330,049 5.36% Shares
JANE STREET GROUP, LLC $182,158 216,006 3.51% Shares
Alyeska Investment Group, L.P. $138,618 164,376 2.67% Shares
BOOTHBAY FUND MANAGEMENT, LLC $112,948 133,936 2.18% Shares
VANGUARD GROUP INC $98,603 87,259 1.90% Shares
GEODE CAPITAL MANAGEMENT, LLC $93,915 111,365 1.81% Shares
Kynam Capital Management, LP $71,175 84,400 1.37% Shares
Dauntless Investment Group, LLC $67,948 80,574 1.31% Shares
VANGUARD FIDUCIARY TRUST CO $45,953 54,511 0.89% Shares
NORTHERN TRUST CORP $31,585 37,454 0.61% Shares
STATE STREET CORP $21,759 25,802 0.42% Shares
XTX Topco Ltd $15,257 18,092 0.29% Shares
BlackRock, Inc. $8,383 9,941 0.16% Shares
Tower Research Capital LLC (TRC) $4,336 5,142 0.08% Shares
HUNTINGTON NATIONAL BANK $3,943 4,676 0.08% Shares
UBS Group AG $2,909 3,451 0.06% Shares
BARCLAYS PLC $1,642 1,947 0.03% Shares
SBI Securities Co., Ltd. $1,451 1,721 0.03% Shares
Federation des caisses Desjardins du Quebec $414 500 0.01% Shares
MORGAN STANLEY $395 468 0.01% Shares
Vanguard Global Advisers, LLC $221 262 0.00% Shares
HRT FINANCIAL LP $76 91,220 0.00% Shares
SG Americas Securities, LLC $12 14,524 0.00% Shares
Virtu Financial LLC $11 12,579 0.00% Shares
Cassaday & Co Wealth Management LLC $6 6 0.00% Shares
HARBOUR INVESTMENTS, INC. $4 5 0.00% Shares
JONES FINANCIAL COMPANIES LLLP $2 2 0.00% Shares
FMR LLC $2 2 0.00% Shares

Activists & 5%+ owners 5 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC ×4 filings May 5, 2026 11.90% Amendment · SEC
Viriom, Inc., Nikolay Savchuk, Iain D. Dukes April 8, 2024 · Initial filing M&A / sale SEC
683 Capital Partners, LP, 683 Capital Management, LLC, Ari Zweiman ×5 filings Feb. 19, 2020 · Initial filing · SEC
Michael B. Hoffman, Michael and Jane Hoffman 2018 Descendants Trust ×3 filings July 27, 2018 · Initial filing Passive investment SEC
E. Premkumar Reddy ×2 filings Feb. 26, 2018 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 35 insiders · 16 officers · 18 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Iain D. Dukes Chief Executive Officer July 9, 2026 A 171,130 0 0 $0
Ramesh Kumar Chief Executive Officer July 26, 2018 A 102,227 0 0 $0
Charles Nolan Parker Chief Financial Officer July 9, 2026 A 15,393 0 0 $0
Mark Patrick Guerin CFO June 18, 2024 M 39,255 0 0 $0
Ajay Bansal Chief Financial Officer Jan. 26, 2016 A 43,846 0 0 $0
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF March 13, 2024 M 74,792 0 0 $0
Thomas J Mckearn President, R&D Jan. 26, 2016 A 3,333 0 0 $0
Nikolay Savchuk Chief Operating Officer July 9, 2026 A 150,606 0 0 $0
Robert Redfield Chief Medical Officer July 9, 2026 A 113,919 0 0 $0
Charles David Pauza Chief Science Officer Virology July 9, 2026 A 115,971 0 0 $0
Victor M Moyo CHIEF MEDICAL OFFICER Oct. 2, 2023 A · 0 0 $0
Mark S. Gelder MD CHIEF MEDICAL OFFICER March 13, 2023 A 10,487 0 0 $0
Abraham N. Oler SVP Corp Dev & Gen Counsel Feb. 7, 2022 A 24,514 0 0 $0
Richard Charles Woodman Chief Medical Officer July 9, 2020 A · 0 0 $0
Manoj Maniar SVP - Product Development July 9, 2020 A 50 0 0 $0
James Altland SVP, Finance & Corp. Develop. Dec. 20, 2013 A 10,000 0 0 $0
Trafford Clarke Director July 9, 2026 A 6,157 0 0 $0
Mary Teresa Shoemaker Director July 9, 2026 A 6,292 0 0 $0
John Harold Leaman Director July 9, 2026 A 4,058 0 0 $0
Werner Cautreels Director July 9, 2026 A 109,222 0 0 $0
Jack E Stover Director July 9, 2026 A 6,165 0 0 $0
Luba Greenwood Director Sept. 16, 2024 A · 0 0 $0
Peter Atadja Director Aug. 10, 2023 A · 0 0 $0
Viren Mehta Director Aug. 10, 2023 A 250,857 0 0 $0
Jerome Groopman Director Aug. 10, 2023 A 10,001 0 0 $0
James J Marino Director Aug. 10, 2023 A 21,334 0 0 $0
Premkumar E Reddy Director Aug. 27, 2020 S 16,683 0 0 $0
Michael B Hoffman Director Aug. 27, 2020 S 0 0 0 $0
Henry S Bienen Director May 29, 2018 P 22,724 0 0 $0
Anne Vanlent Director June 15, 2015 A · 0 0 $0
TPAV, LLC 10% owner Dec. 29, 2024 P · 0 0 $0
TYNDALL CAPITAL PARTNERS L P 10% owner Sept. 24, 2019 S 616,389 0 0 $0
683 Capital Management, LLC 10% owner April 27, 2018 P 14,503,169 0 0 $0
Baxter Healthcare SA 10% owner May 6, 2015 J 0 0 0 $0
Michael & Jane Hoffman 2013 Descendants 10% owner Feb. 21, 2014 P 4,518,275 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 2 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
VXF · VANGUARD INDEX FUNDS 0.00% 152,849 SH Aug. 19, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.00% 177,200 SH Aug. 19, 2026 Daily

TRAW Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 7 analysts SELL
Median target $1.00 +75.9%
0 0.0% Strong Buy
0 0.0% Buy
4 57.1% Hold
1 14.3% Sell
2 28.6% Strong Sell

12-Month Price Target

1 analysts · 2026-09-30

Mean target $1.00 +75.9%

Low$1.00 Mean$1.00 High$1.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
TRAW · 1.4 1134.5% · · ·
KPRX $7M -0.7 · · -56.6% ·
CALC · -3.3 -29.7% · · ·
ADIL $244.4K -0.0 · · -146.8% ·
CNSP · -0.1 · · · ·
CURX $9M -1.9 · · -73.3% ·
JAGX · -0.0 -1.5% -465.4% 907.4% ·
LLY · 46.8 44.7% 31.7% 101.2% ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 14, 2026